Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beam Therapeutics (BEAM) Equity Average (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Equity Average for 7 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly Equity Average rose 44.56% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 44.56% year-over-year, with the annual reading at $986.0 million for FY2025, 14.99% up from the prior year.
  • Equity Average for Q4 2025 was $1.1 billion at Beam Therapeutics, up from $1.0 billion in the prior quarter.
  • The five-year high for Equity Average was $1.1 billion in Q4 2025, with the low at $334.0 million in Q1 2021.
  • Average Equity Average over 5 years is $811.6 million, with a median of $818.7 million recorded in 2022.
  • The sharpest move saw Equity Average surged 1007.96% in 2021, then decreased 13.84% in 2022.
  • Over 5 years, Equity Average stood at $840.3 million in 2021, then dropped by 13.84% to $724.0 million in 2022, then rose by 21.57% to $880.1 million in 2023, then decreased by 13.37% to $762.4 million in 2024, then skyrocketed by 44.56% to $1.1 billion in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $1.1 billion, $1.0 billion, and $1.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.